

# ForPatients

by Roche

Idiopathic Pulmonary Fibrosis (IPF)

## A Study to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

**Trial Status**  
Terminated

**Trial Runs In**  
35 Countries

**Trial Identifier**  
NCT04552899 2020-000791-38  
WA42293

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT04552899 2020-000791-38 WA42293**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=40 Years & <= 85 Years

**Healthy Volunteers**  
No

---